Tauroursodeoxycholic acid (TUDCA) 14605-22-2

Taurodeoxycholic acid (TUDCA), also known as 3 α, 7 β dihydroxycholanyl-N-Taurine, is a conjugated bile acid formed by the condensation between the carboxyl group of ursodeoxycholic acid (UDCA) and the amino group of taurine.

The modern synthetic drug taurodeoxycholic acid is a conjugated bile acid formed by the condensation between the acetyl group of ursodeoxycholic acid and the amino group of taurine. Ursodeoxycholic acid capsules have been launched overseas and were approved for sale in China as an imported drug in 2007. They are mainly used clinically to treat gallbladder cholesterol stones, primary sclerosing cholangitis, primary biliary cirrhosis, and chronic hepatitis C. At present, there is no drug registration for taurodeoxycholic acid raw materials and their preparations in China. Sodium taurodeoxycholic acid is a natural bile acid isolated from bear bile juice. It is a chemical preparation that combines with taurine in the body and exists in bile. It is a hydrophilic bile acid and a cholesterol stone dissolving agent. It can reduce the secretion of cholesterol by the liver, lower the saturation of cholesterol in bile, promote the secretion of bile acids, increase the solubility of cholesterol in bile, dissolve cholesterol stones or prevent the formation of stones. It can increase the secretion of bile, relax the sphincter muscle of the bile duct, and produce a choleretic effect, which is beneficial for the expulsion of stones. This product cannot dissolve other types of gallstones. Suitable for treating cholesterol stones, hyperlipidemia, bile secretion disorders, primary biliary cirrhosis, chronic hepatitis, bile reflux gastritis, and preventing acute rejection and reactions in liver transplantation. The stone dissolving effect of this product is slightly weaker than that of chenodeoxycholic acid.

TUDCA was discovered in bear bile in 1902. It is the main bile acid in bear bile and has functions such as spasmolytic, anticonvulsant, anti-inflammatory, and cholelithiasis dissolving. Tauroursodeoxycholic acid (1) is an active ingredient in bear bile, with a chemical name of 2- [[[(3 α, 5 β, 7 β) -3,7-dihydroxy-24-oxocholestan-24-yl] amino] ethanesulfonic acid dihydrate. It was developed by the Italian pharmaceutical company Besidi and first launched in Italy in 1991. In 2007, it was approved for sale in China under the trade name taurolite. It is mainly used clinically to treat gallbladder cholesterol stones, primary sclerosing cholangitis, primary biliary cirrhosis, and chronic hepatitis C. Clinical studies have shown that compared with ursodeoxycholic acid, 1 has faster stone dissolution rate, higher complete dissolution rate, and no significant adverse reactions.